# EDGAR Filing Document

**Accession Number:** 0002025774
**File Stem:** 0001493152-26-007695
**Filing Date:** 2026-2
**Character Count:** 8716
**Document Hash:** 85be882d553118410ce0188bbe8c9e45
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-007695.hdr.sgml**: 20260223

**ACCESSION NUMBER**: 0001493152-26-007695

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260223

**FILED AS OF DATE**: 20260223

**DATE AS OF CHANGE**: 20260223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Alps Group Inc
- **CENTRAL INDEX KEY:** 0002025774
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HEALTH SERVICES [8000]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42915
- **FILM NUMBER:** 26662249

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** UNIT E-18-01 & E-18-02, LEVEL 18,
- **STREET 2:** ICON TOWER (EAST), NO.1,JALAN 1/68F,
- **CITY:** KUALA LUMPUR
- **PROVINCE COUNTRY:** N8
- **BUSINESS PHONE:** 60321631113

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** UNIT E-18-01 & E-18-02, LEVEL 18,
- **STREET 2:** ICON TOWER (EAST), NO.1,JALAN 1/68F,
- **CITY:** KUALA LUMPUR
- **PROVINCE COUNTRY:** N8

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Alps Global Holding Pubco
- **DATE OF NAME CHANGE:** 20240604

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of February 2026**

**Commission File Number: 001-42915**

**Alps Group Inc**

**(Registrant's Name)**

**Unit E-18-01 & E-18-02, Level 18, Icon Tower (East)**

**No. 1, Jalan 1/68F, Jalan Tun Razak**

**50400 Kuala Lumpur**

**Wilayah Persekutuan, Malaysia**

**(Address of Principal Executive Offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

**Information Contained in this Form 6-K Report**

Attached hereto as Exhibit 99.1 is a press release dated February 23, 2026 issued by Alps Group Inc relating to a peer-reviewed case study in the February 2026 edition of SAGE Open Medical Case Reports that highlights the effectiveness of Autologous Immune Enhancement Therapy.

Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1\* | [Press Release dated February 23, 2026](ex99-1.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Alps Group Inc** | **Alps Group Inc** |
| Date: February 23, 2026 | By: | */s/ Dr. Tham Seng Kong* |
|  | Name: | Dr. Tham Seng Kong |
|  | Title: | Chief Executive Officer and Director |

---

## Exhibit 99.1

**Exhibit 99.1**

**Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture Protocol**

KUALA LUMPUR, Malaysia, February 23, 2026 - Alps Group Inc (the "Company" or "Alps Group"), the parent company of Alps Life Sciences Inc. ("Alps Holdco"), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced a peer-reviewed case study in the February 2026 edition of *SAGE Open Medical Case Reports*.

The publication reports findings from nine patients who received autologous Natural Killer (NK) cell infusions produced using the Company's in-house developed culture protocol. Natural Killer (NK) cells are a type of immune cell involved in the body's natural defense against abnormal cells.

The patients were monitored pre- and post-infusion for hematological parameters, liver function, hypersensitivity reactions, inflammatory markers as well as tumor markers to assess for potential NK cell-induced or any dose-dependent toxic/adverse reactions. The study provided evidence of clinical tolerability of the autologous NK cells cultured using the Company's proprietary protocol.

The clinical case series study was registered with the National Medical Research Register, Ministry of Health Malaysia, with NMRR ID 25-00333-MUM. Data collection and analysis were conducted in accordance with the ethical principles of the Declaration of Helsinki and Malaysian Good Clinical Practice guidelines. The study involved nine nonconsecutive patients who received NK cell infusions at ALPS Medical Centre between 2023 and 2024.

Dr. Tham Seng Kong, Chief Executive Officer of Alps Group, stated, *"Based on these preliminary observations, our in-house developed NK cells appear to be safe for use. The NK cells also exhibited cytotoxicity toward in vitro cultured and co-incubated cancer cell models; however, this was assessed using pilot cultures rather than as part of batch-release testing."*

A notable aspect of this case series is the Company's patent-pending, antibody-free culture method (Malaysian patent application no. PI2025002484) which enables cost-effective, large-scale production of highly pure natural killer (NK) cells using basic culture media and autologous plasma. This approach improves the safety profile of NK cells and lowers manufacturing barriers, potentially making advanced immunotherapy more accessible and efficient.

Preliminary case series data supports the safety of this method, positioning Alps Group at the forefront of scalable, next-generation autologous immune cell therapy solutions. Together with preclinical GLP study data, the findings from this study are intended to support the design of future clinical investigations in a broader patient population.

**Details of the study and its findings have been peer-reviewed and published in *SAGE Open Medical Case Reports*, accessible at:**

**<u>https://journals.sagepub.com/doi/epub/10.1177/2050313X251376950</u>**

**About Alps Group**

Alps Group Inc is the parent company of Alps Life Sciences Inc., an integrated biotechnology platform integrating research and development, medical services, and wellness solutions of advanced therapies under one unified ecosystem aimed at improving healthcare outcomes globally. Alps Group's mission is to create a fair healthcare ecosystem, to make advance predictive, preventive, and precision medicine accessible and affordable

**Forward-Looking Statements**

Certain statements in this press release may be considered to contain certain "forward-looking statements" within the meaning of "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "shall," "may," "anticipate," "estimate," "would," "positioned," "future," "forecast," "intend," "plan," "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company management's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

A further list and description of risks and uncertainties can be found in documents filed with the Securities and Exchange Commission ("SEC") by the Company and other documents that we may file or furnish with the SEC, which you are encouraged to read. Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.

**Investor Relations Contact**

Andrew J. Barwicki

Tel: 516-662-9461

Email: andrew@barwicki.com